Anthem Biosciences Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹179(31.40%)
Premium (ELP)
Anthem Biosciences Limited's successfully transitioned to public market status with its listing on NSE, BSE on Jul 21, 2025. The IPO mobilized 5,95,61,404 Shares in cumulative capital, including TBD for corporate expansion and ₹3395.00 Cr for shareholder liquidity management.
The public offering was conducted within the price parameters of ₹540 to ₹570, with minimum investment lots of 26 shares. subscription activity between Jul 14, 2025 and Jul 16, 2025 demonstrated market reception to the company's valuation and growth narrative.
The allotment process concluded on Jul 17, 2025, finalizing share distribution to successful bidders. The listing represents a transformational event, providing the company with enhanced market visibility, regulatory compliance framework, and access to diversified investor capital.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Founded in 2006, Anthem Biosciences Limited is a Contract Research, Development, and Manufacturing Organization (CRDMO) that provides comprehensive services throughout the drug development process—from discovery to manufacturing. The company specializes in producing fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, vitamin analogues, and biosimilars. It supports the full journey of commercial molecules, right from initial research to market launch. By September 30, 2024, Anthem had built a global presence, serving more than 425 clients in over 44 countries, including key markets like the U.S., Europe, and Japan. Its clientele ranges from small biotech startups to major pharmaceutical companies. Anthem is actively engaged in research and development, with 196 projects underway at different stages, including discovery, early and late development phases, and commercial production. The company also focuses on innovation, holding 8 granted patents (1 in India and 7 internationally), along with 24 pending patent applications worldwide. The company’s workforce, as of September 2024, consists of 600 professionals, including skilled chemists, biologists, and engineers with expertise across various scientific and technical fields.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- End-to-end CRDMO capabilities across small and large molecules with integrated services from discovery to commercial manufacturing, making it the fastest-growing Indian CRDMO with presence in all three segments.
- Focused business model targets emerging pharma and biotech firms needing external expertise, regulatory support, and scalable manufacturing.
- Scalable and compliant manufacturing infrastructure with two cGMP facilities and 142 kL capacity (expanding to 182 kL), backed by major capital investments.
- Regulatory compliance and inspection delays by authorities like USFDA and PMDA may disrupt manufacturing and impact revenue due to approval or compliance issues.
- Heavy reliance on manufacturing units (Unit I, II, and upcoming Unit III) exposes the company to risks from delays, labor shortages, or material issues affecting CRDMO and specialty ingredient operations.
- Exposure to hazardous materials increases operational risks despite safety upgrades, with potential for accidents, operational disruption, or damage to people and property.
- Ajay Bhardwaj
- Ganesh Sambasivam
- K Ravindra Chandrappa
- Ishaan Bhardwaj
Anthem Biosciences Limited
Kfin Technologies Limited